<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00011479</url>
  </required_header>
  <id_info>
    <org_study_id>P1018</org_study_id>
    <secondary_id>11653</secondary_id>
    <secondary_id>ACTG P1018</secondary_id>
    <secondary_id>PACTG P1018</secondary_id>
    <nct_id>NCT00011479</nct_id>
  </id_info>
  <brief_title>Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents</brief_title>
  <official_title>Single Dose Pharmacokinetic Study of Abacavir in HIV-Infected Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure blood levels of abacavir in children and adolescents&#xD;
      over a period of time following a single dose so that a dosage for adolescents can be&#xD;
      determined.&#xD;
&#xD;
      Little is known about how abacavir is cleared by the body in adolescents. It has been shown&#xD;
      that young children require a higher abacavir dose based on weight than adults. Older&#xD;
      children, or adolescents, may not require as high a dose. This study may provide information&#xD;
      as to whether the children's dose or the adult dose is better for HIV-infected adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetic differences between children and adults have resulted in recommended doses of&#xD;
      abacavir based on weight that are higher for children than for adults. There are insufficient&#xD;
      data to determine whether the pediatric or adult dose is more appropriate for HIV-infected&#xD;
      adolescent patients. This study measures pharmacokinetic data for abacavir in the adolescent&#xD;
      population so that an appropriate dosage can be determined.&#xD;
&#xD;
      Patients are evenly enrolled into 2 groups based on Tanner Stage. Group I patients are Tanner&#xD;
      Stage 1 or 2 (pre-pubertal). Group II patients are Tanner Stage 3, 4, or 5 (pubertal). Each&#xD;
      patient receives a single oral dose of abacavir given as the commercially available oral&#xD;
      solution. Pharmacokinetic blood samples are collected before dosing and at 0.5, 1.0, 1.5,&#xD;
      2.0, 2.5, 3.0, 4, 6, and 8 hours post dose for abacavir concentrations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">August 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients may be eligible for this study if they:&#xD;
&#xD;
          -  Are 9 to 18 years of age.&#xD;
&#xD;
          -  Are HIV-positive.&#xD;
&#xD;
          -  Have a CD4 cell count above 200 cells/microL.&#xD;
&#xD;
          -  Have a viral load (level of HIV in the blood) under 100,000 copies/ml.&#xD;
&#xD;
          -  Have not changed their anti-HIV drugs for the 4 weeks before study entry.&#xD;
&#xD;
          -  Are able to swallow study medications.&#xD;
&#xD;
          -  Both males and females, agree to use a barrier method of birth control for 3 days&#xD;
             after taking the abacavir dose for this study. (This study has been changed. In the&#xD;
             earlier version, no birth control was needed.)&#xD;
&#xD;
          -  Can be followed at a participating Pediatric AIDS Clinical Trials Unit (PACTU) for the&#xD;
             entire study.&#xD;
&#xD;
          -  Provide written consent of a parent or guardian, if under 18 years of age.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients will not be eligible for this study if they:&#xD;
&#xD;
          -  Have liver or kidney problems, as shown by screening tests.&#xD;
&#xD;
          -  Have medical or surgical problems that affect movement or absorption in the stomach or&#xD;
             gut.&#xD;
&#xD;
          -  Have an opportunistic (AIDS-related) or serious bacterial infection requiring medicine&#xD;
             at the time of enrollment.&#xD;
&#xD;
          -  Have any diseases (other than HIV infection) or other findings that, in the&#xD;
             investigator's opinion, might make it harmful for the patient to be on the study.&#xD;
&#xD;
          -  Have a history of chronic alcohol use.&#xD;
&#xD;
          -  Fall outside of a certain weight range for their age.&#xD;
&#xD;
          -  Are pregnant or breast-feeding.&#xD;
&#xD;
          -  Are receiving or have received abacavir.&#xD;
&#xD;
          -  Are receiving nonnucleoside reverse transcriptase inhibitors, including efavirenz,&#xD;
             delavirdine, or nevirapine; hydroxyurea; mycophenylate; rifampin, rifabutin,&#xD;
             anticonvulsants, or other drugs that affect the liver; or chemotherapy for active&#xD;
             cancer.&#xD;
&#xD;
          -  Have received interferons, interleukins, HIV or other vaccines, or experimental&#xD;
             therapy within 30 days before entering the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence D'Angelo</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>John Rodman</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham - Pediatric</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of L.A. (Pediatric)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp of Washington DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>200102916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Florida Health Science Ctr / Pediatrics</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami (Pediatric)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Med Ctr Inc</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's Memorial Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606143394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Chicago Children's Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606371470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>021155724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Medicine &amp; Dentistry of New Jersey / Univ Hosp</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>071032714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Med Ctr Adolescent AIDS Program</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Med Ctr</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>146420001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Univ of New York at Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>117948111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>277103499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Children's Hosp</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>432052696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Univ of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>294253312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hosp of Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>381052794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Med Ctr of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp / Baylor Univ</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1361</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2001</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Administration, Oral</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>abacavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

